| First Author | Coulson RL | Year | 2024 |
| Journal | iScience | Volume | 27 |
| Issue | 4 | Pages | 109259 |
| PubMed ID | 38510125 | Mgi Jnum | J:352333 |
| Mgi Id | MGI:7615788 | Doi | 10.1016/j.isci.2024.109259 |
| Citation | Coulson RL, et al. (2024) Translational modulator ISRIB alleviates synaptic and behavioral phenotypes in Fragile X syndrome. iScience 27(4):109259 |
| abstractText | Fragile X syndrome (FXS) is caused by the loss of fragile X messenger ribonucleoprotein (FMRP), a translational regulator that binds the transcripts of proteins involved in synaptic function and plasticity. Dysregulated protein synthesis is a central effect of FMRP loss, however, direct translational modulation has not been leveraged in the treatment of FXS. Thus, we examined the effect of the translational modulator integrated stress response inhibitor (ISRIB) in treating synaptic and behavioral symptoms of FXS. We show that FMRP loss dysregulates synaptic protein abundance, stabilizing dendritic spines through increased PSD-95 levels while preventing spine maturation through reduced glutamate receptor accumulation, thus leading to the formation of dense, immature dendritic spines, characteristic of FXS patients and Fmr1 knockout (KO) mice. ISRIB rescues these deficits and improves social recognition in Fmr1 KO mice. These findings highlight the therapeutic potential of targeting core translational mechanisms in FXS and neurodevelopmental disorders more broadly. |
